An Early Phase 1 interventional study of 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use in HPV Infection, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair. Active, not recruiting at 1 site in United States. Open to female participants aged 24 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-05-20.
Sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · Early Phase 1, Interventional, and Health services research
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients.
576 studies on the registry are indexed under Papillomavirus Infections; 132 are open to participants now.
This study's planned enrollment of 20 is below the median of 235 across 402 interventional studies indexed under Papillomavirus Infections.
Browse Papillomavirus Infections studies →Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix that suggests the potential for clinical benefit of HPV patients.
20 Cervical HPV Infection Patients
Inclusion Criteria:
Exclusion Criteria:
Therapeutic Biological Product Mix activity 9vHPV Vaccine 1.0 mL add into BCG Organism 50 MG
Biological: 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
By the percutaneous route with the multiple puncture device - 9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix
Also known as: 9vHPV Vaccine plus BCG Organism Mix
20 HPV Participants with HPV testing by standard PCR assay
Negative testing HPV by standard PCR assay after percutaneous 21 days
Time frame: Duration at least 28 days
20 HPV Participants with IGRA blood test with HPV protein antigen
Positive IGRA blood test with HPV protein antigen after percutaneous use 21 days
Time frame: Duration at least 28 days
20 HPV Participants with IGRA blood test with TB antigens
* Negative IGRA blood test with TB antigens before percutaneous use * Positive IGRA blood test with TB antigens after percutaneous use 21 days
Time frame: Duration at least 28 days
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair